EP. 1: City of Hope’s Afkhami Discusses NSCLC With EGFR Exon 20 Insertion-Positive MutationsJuly 1st 2022
Michelle Afkhami, MD, of City of Hope, joins The American Journal of Managed Care® (AJMC®) for a discussion on EGFR exon 20 insertion positive mutations in non-small cell lung cancer.
EP. 2: Targeted Therapies Bring “Proven Benefits” for Patients With EGFR Exon 20 Insertion+ NSCLC, Ramalingam SaysSeptember 12th 2022
Suresh Ramalingam, MD, FACP, FASCO, a professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, is the executive director of the Winship Cancer Institute and associate vice president for cancer, Woodruff Health Sciences Center, Atlanta, Georgia. Ramalingham spoke with The American Journal of Managed Care® (AJMC®) about the current treatment and research landscape involving EGFR Exon 20 insertion+ NSCLC.
EP. 3: Edward Arrowsmith, MD, MPH, Discusses EGFR Exon 20 Insertion+ NSCLC, How Knowledge Fits Into PathwaysOctober 1st 2022
Edward Arrowsmith, MD, MPH, medical director for clinical pathways for OneOncology, discussed treatment challenges in EGFR Exon 20 insertion+ non-small cell lung cancer (NSCLC) and best practices in use of clinical pathways.
EP. 4: Roy Beveridge, MD, Discusses Pathways, NCCN Guidelines in EGFR Exon 20 Insertion+ NSCLCOctober 12th 2022
Beveridge, now with Avalere Health, addressed the importance of clinical pathways in selecting therapies in non-small cell lung cancer (NSCLC) and the emergence of options for EGFR Exon 20 Insertion+ NCSLC.
EP. 5: Dr Joshua Sabari: “Tissue Is the Issue” in NGS for EGFR Exon 20 Insertion+ NSCLCNovember 17th 2022
Joshua Sabari, MD, assistant professor of medicine, Medical Oncology, Perlmutter Cancer Center at NYU Langone Health, New York, New York, discusses topics involving next generation sequencing (NGS) to develop molecular profiles in the treatment of non-small cell lung cancer (NSCLC).
EP. 6: Marcia Horn Discusses Advancements in EGFR Exon 20 Insertion+ NSCLC and the Importance of CommunityDecember 15th 2022
There are promising developments in the pipeline for EGFR exon 20 insertion–positive non–small cell lung cancer (NSCLC), and groups like The Exon 20 Group can help ensure patients are getting access to programs to navigate their care.